Tau-Lowering Drug Diranersen Slowed Early Alzheimer's Decline 38% at Two Years in Biogen's Open-Label Extension Data
Biogen reported that experimental tau-lowering drug diranersen slowed decline by 38% after two years in a low-dose group, but the open-label findings are not randomized or approved treatment evidence.
Medical Daily ·